Amundi Trims Stock Holdings in Bruker Co. (NASDAQ:BRKR)

Amundi lessened its position in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 49.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 8,981 shares of the medical research company's stock after selling 8,764 shares during the quarter. Amundi's holdings in Bruker were worth $542,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in BRKR. True Wealth Design LLC increased its position in shares of Bruker by 4,636.4% during the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company's stock worth $36,000 after buying an additional 510 shares during the period. Eagle Bay Advisors LLC grew its holdings in Bruker by 2,324.1% during the 4th quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock worth $41,000 after acquiring an additional 674 shares during the period. UMB Bank n.a. raised its position in shares of Bruker by 37.5% in the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock worth $53,000 after acquiring an additional 248 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Bruker by 47.5% in the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock valued at $75,000 after purchasing an additional 412 shares during the period. Finally, Blue Trust Inc. boosted its position in shares of Bruker by 13.5% during the 4th quarter. Blue Trust Inc. now owns 2,164 shares of the medical research company's stock valued at $127,000 after purchasing an additional 257 shares in the last quarter. Institutional investors own 79.52% of the company's stock.

Remove Ads

Bruker Stock Performance

BRKR traded up $0.05 during midday trading on Monday, reaching $44.50. The company had a trading volume of 2,055,182 shares, compared to its average volume of 1,311,650. The business has a 50-day moving average price of $52.16 and a two-hundred day moving average price of $57.64. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. Bruker Co. has a 12-month low of $43.51 and a 12-month high of $94.64. The stock has a market cap of $6.75 billion, a PE ratio of 58.55, a P/E/G ratio of 2.16 and a beta of 1.18.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. On average, sell-side analysts expect that Bruker Co. will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be paid a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date is Monday, March 17th. Bruker's dividend payout ratio is currently 26.32%.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Guggenheim restated a "buy" rating on shares of Bruker in a report on Monday, February 24th. The Goldman Sachs Group upgraded Bruker from a "sell" rating to a "neutral" rating and set a $60.00 target price on the stock in a report on Thursday, December 5th. Bank of America boosted their price target on shares of Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a research note on Friday, December 13th. UBS Group began coverage on shares of Bruker in a research note on Tuesday, December 10th. They issued a "neutral" rating and a $66.00 price objective on the stock. Finally, Barclays decreased their target price on shares of Bruker from $69.00 to $65.00 and set an "overweight" rating for the company in a research report on Monday, February 10th. Six equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat, Bruker has a consensus rating of "Moderate Buy" and a consensus price target of $70.50.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.